Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | XBP1 | P17861 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.63 |
| ▸ | MEN1 | O00255 | 5/20 | 0.63 |
| ▸ | PNLIP | P16233 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | IDE | P14735 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29502491 | 0.84 | MAPT (0.72) | MAPTPOLBXBP1NPC1RAB9A | |
| Koenimbine SCHEMBL29581663 | 0.82 | MAPT (0.69) | MAPTPOLBXBP1NPC1RAB9A | |
| SCHEMBL30929792 | 0.82 | MAPT (0.69) | MAPTPOLBXBP1NPC1RAB9A | |
| SCHEMBL3310991 | 0.81 | MAPT (0.66) | MAPTPOLBXBP1NPC1RAB9A | |
| SCHEMBL30929796 | 0.79 | MAPT (0.65) | MAPTPOLBXBP1NPC1RAB9A | |
| Mahanimbine SCHEMBL2991765 | 0.78 | MAPT (1.00) | MAPTPOLBXBP1NPC1RAB9A | |
| Mahanimbine SCHEMBL18488203 | 0.78 | MAPT (1.00) | MAPTPOLBXBP1NPC1RAB9A | |
| Mahanimbine SCHEMBL18488200 | 0.78 | MAPT (1.00) | MAPTPOLBXBP1NPC1RAB9A | |
| SCHEMBL29814874 | 0.77 | MAPT (0.62) | MAPTPOLBXBP1NPC1RAB9A | |
| SCHEMBL31324179 | 0.75 | MAPT (0.60) | MAPTPOLBXBP1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114272323-A | Traditional Chinese medicine formula for regulating and controlling intestinal function of lactating women | 华子昂 | 2022-04-05 | — | — | CN | claimed |
| US-20250281559-A1 | DRUG FOR TREATMENT OF BREAST CANCER WITH ANTLER AND GINSENG AS SOVEREIGN DRUG AND PREPARATION METHOD AND APPLICATION THEREOF | JILIN UNIVERSITY (CN) | 2025-09-11 | — | — | US | disclosed |
| EP-4099976-B1 | MURRAYA KOENIGII EXTRACT AND USE THEREOF IN COSMETICS | GATTEFOSSE SAS (FR) | 2024-12-04 | — | — | EP | disclosed |
| US-20240390446-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY DISEASES INCLUDING DIABETES AND THYROID DISEASES | ALKALAY RACHEL (IL) | 2024-11-28 | — | — | US | disclosed |
| EP-4404923-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY DISEASES INCLUDING DIABETES AND THYROID DISEASES | Alkalay, Rachel (IL) | 2024-07-31 | — | — | EP | disclosed |
| US-20240226218-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING A CORONAVIRUS INFECTION | Novel Concepts Medical Ltd (IL) | 2024-07-11 | — | — | US | disclosed |
| CN-118141926-A | Application of plant carbazole alkaloid in preparation of iron death inhibitor | 北京大学 | 2024-06-07 | — | — | CN | disclosed |
| CN-117059172-A | Method for analyzing action mechanism of ginseng for improving erection dysfunction | 广州康兮乐健康科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20230346866-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NON-MALIGNANT RESPIRATORY DISEASE | Novel Concepts Medical Ltd (IL) | 2023-11-02 | — | — | US | disclosed |
| US-20230181665-A1 | TREATING OR PREVENTING INFLAMMATORY DISEASES INCLUDING DIABETES MELLITUS 10 TYPE I AND TYPE II AND THYROID DISEASES | Novel Concepts Medical Ltd (IL) | 2023-06-15 | — | — | US | disclosed |
| US-20180052161-A1 | BIOMARKERS FOR MALARIA DIAGNOSIS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2018-02-22 | — | — | US | disclosed |
| WO-2016149386-A1 | BIOMARKERS FOR MALARIA DIAGNOSIS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2016-09-22 | — | — | WO | disclosed |
| US-20090104297-A1 | HERBAL COMPOSITION FOR TREATMENT OF INFECTIONS CAUSED BY DERMATOPHYTES | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2009-04-23 | — | — | US | disclosed |
| CN-100478022-C | Synergistic composition for treating hyperlipidemia | COUNCIL SCIENT IND RES (IN) | 2009-04-15 | — | — | CN | disclosed |
| EP-1998727-A2 | HERBAL COMPOSITION FOR TREATMENT OF INFECTIONS CAUSED BY DERMATOPHYTES | Piramal Life Sciences Limited (IN) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007110837-A2 | HERBAL COMPOSITION FOR TREATMENT OF INFECTIONS CAUSED BY DERMATOPHYTES | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2007-10-04 | — | — | WO | disclosed |
| CN-1893965-A | Synergistic composition for treating hyperlipemia | COUNCIL SCIENT IND RES (IN) | 2007-01-10 | — | — | CN | disclosed |
| US-6989165-B2 | Synergistic composition for treating hyperilipdemia | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-01-24 | — | — | US | disclosed |
| WO-2005070442-A1 | A SYNERGISTIC COMPOSITION FOR TREATING HYPERLIPIDEMIA | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2005-08-04 | — | — | WO | disclosed |
| US-20050136138-A1 | Synergistic composition for treating hyperilipdemia | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390446-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY DISEASES INCLUDING DIABETES AND THYROID DISEASES | TPO, TNF, ADAMTS13 | MAPT 2143/4885POLB 4693/4885XBP1 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.